For research use only. Not for use in humans.

Tremelimumab (anti-CTLA-4)

Synonyms: Ticilimumab, CP-675,206 Cat.No.A2021 Purity:99.87%

Tremelimumab (Ticilimumab, CP-675,206) is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes.

1 Citation

17 Nobel Prize winners
have used Selleck products

Shimon Sakaguchi

Nature Communications 2025;16, Article number:1325

David Baker

Dev Cell 2023;58(20):2163-2180.e9.

Michael Houghton

Cell Chem Biol 2020;27(7):780-792.e5

David Julius

Cell 2017;185-198.e16

Charles M. Rice

Cell 2018;172(3):423-438.e25

Quality Control

Batch: Purity: 99.87% Protein concentration: 8.05mg/ml Endotoxin Level: <1 EU/mg

99.87

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Tremelimumab (Ticilimumab, CP-675,206) is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes.
References	[1] https://pubmed.ncbi.nlm.nih.gov/27816492/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	745013-59-6
Molecular Weight	146.4 kDa
Isotype	Human IgG2
Source	HEK293 Cells
Purification	Protein G
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.